title: Animal models for benign prostatic hyperplasia.
abstract: Although the etiology of benign prostatic hyperplasia (BPH) is unknown, various animal models have been used for several decades to identify potential therapeutic approaches. These models can be divided into those measuring smooth muscle tone and those measuring cellular proliferation. Animal models have played an important role in the development of the two drug classes currently approved for the treatment of BPH: the α-adrenoceptor antagonists and the steroid 5-α-reductase inhibitors. However, models measuring prostatic tone have not been particularly useful in the identification of new α-adrenoceptor antagonists having advantages over currently available drugs, and it is not certain that reduction of prostatic smooth muscle tone is responsible for the relief of BPH symptoms. A further limitation with BPH models is that prostatic hyperplasia similar to the human condition does not occur spontaneously or cannot be induced in any suitable animal species. The identification of a more useful BPH model is focused on cellular mechanisms of prostatic growth, looking similarities between humans and experimental animals.
authors.affiliation: Department of Urology Research, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA.
authors.forename: J Paul
authors.initials: JP
authors.lastname: Hieble
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects / Q000503:physiopathology; D011467:Prostate / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D015203:Reproducibility of Results; D013045:Species Specificity
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists